enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. 7+3 (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/7+3_(chemotherapy)

   "7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...

3. ADE (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/ADE_(chemotherapy)

   ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy. ADE regimen consists of three drugs:

4. Chemotherapy regimen - Wikipedia

   en.wikipedia.org/wiki/Chemotherapy_regimen

   A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...

5. Acute myelomonocytic leukemia - Wikipedia

   en.wikipedia.org/wiki/Acute_myelomonocytic_leukemia

   Chemotherapy is broken down into 2 phases: Induction therapy: first short and invasive phase of treatment with the goal to clear the blood of blasts and reduce the number of blasts in the bone marrow back to normal. [12] Consolidation therapy: second phase given in cycles that occur after the patient has recovered from induction therapy.

6. R-HDAC - Wikipedia

   en.wikipedia.org/wiki/R-HDAC

   HDAC is also used as a consolidation regimen in acute myeloid leukemia after initial 7+3 induction. HDAC also can be used as the primary induction therapy in AML, with higher than in 7+3 success (remission) rate, but it is more toxic and causes more treatment-related complications and treatment-related mortality than 7+3 when used as primary ...

7. Medical use of arsenic trioxide - Wikipedia

   en.wikipedia.org/wiki/Medical_use_of_arsenic...

   Arsenic trioxide is intended for the induction of remission and consolidation in adult patients with acute promyelocytic leukemia who have the t(15;17) translocation and/or the PML/RARα gene. The drug should be used after treatment failure or relapse. Prior therapy should include retinoid and chemotherapy. [70]

8. Hyper-CVAD - Wikipedia

   en.wikipedia.org/wiki/Hyper-CVAD

   Hyper-CVAD chemotherapy is generally reserved for use in the treatment of serious and aggressive forms of hematological malignancy. There are serious side effects and complications arising from the administration of the various agents, which require careful management in an appropriate health-care setting.

9. T-cell acute lymphoblastic leukemia - Wikipedia

   en.wikipedia.org/wiki/T-cell_acute_lymphoblastic...

   Currently, standard treatment for T-cell acute lymphoblastic leukemia (T-ALL) involves long-term chemotherapy and medication to prevent or treat side effects associated with low white blood cell counts resulting from intensive chemotherapy regimens. The treatment typically occurs in three stages: induction, consolidation, and maintenance. [3]